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Abstract  
Objectives: This study examined views of pharmacy staff regarding the safety of e-cigarettes 
compared to nicotine replacement therapies (NRTs) and conventional cigarettes, as well as 
views on their regulation in Australia. 
Methods: We conducted a cross-sectional survey among pharmacy staff (64 pharmacists and 
76 pharmacy assistants) from the greater Brisbane region, Queensland, Australia. The self-
administered questionnaire included closed- and open-ended questions that explores 
pharmacy staff perception on harms of e-cigarettes versus NRT and traditional cigarettes, 
knowledge of current e-cigarette regulations, views on how they should be regulated and 
information needs regarding e-cigarettes. Pearson’s chi-square test was employed for 
computing differences between variables. A content analysis of responses to open-ended 
questions was also performed. 
Results: Over 90% of pharmacy staff regarded e-cigarettes without nicotine and NRTs as 
less harmful than regular tobacco cigarettes. This reduced to 72% for e-cigarettes containing 
nicotine, with 24% of respondents believing they are equally as harmful as conventional 
cigarettes. Moreover, few respondents were confident about the short and long term safety of 
e-cigarettes containing nicotine (36% and 15% respectively) whereas pharmacy staff were 
more comfortable with the safety of NRTs for short (88%) and long term (35%) use. The 
majority of respondents believed that e-cigarettes with nicotine should be regulated as a 
medicine, either requiring a prescription (24%) or sold only by pharmacies (22%), though 
many believed that they should be regulated in the same way as regular tobacco cigarettes 
(27%). Some pharmacy staff (39%) reported having been asked about e-cigarettes by 
customers and 75% believed that their customers would be interested in using e-cigarettes as 
a smoking cessation aid.   
Conclusions: There is a need to provide evidence-based and customised education for 
pharmacists regarding e-cigarettes to help them guide their clients.  
 
Key words: Electronic cigarettes, ENDS, Community pharmacist, Australia  
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1. Introduction  
Being located at the heart of the community and widely distributed geographically, 
community pharmacies provide a unique platform to deliver proactive public health services 
such as smoking cessation support (1). A recent systematic review and meta-analysis that 
examined the impact of community pharmacy-led smoking cessation interventions concluded 
that pharmacist-led behavioural support together with the use of nicotine replacement 
therapies (NRTs) leads to a higher quit rate compared to unassisted quit attempts or standard 
cessation advice plus NRTs (2). Although smoking cessation advice and approved 
pharmacological smoking cessation aids including varenicline, bupropion and a range of 
NRTs (3) (4) are widely available in high income countries, such as Australia, an increasing 
number of smokers are using electronic nicotine delivery systems, or e-cigarettes, as a 
cessation aid or lower risk alternative to conventional cigarettes (5, 6). 
According to a national survey conducted by the Australian Institute of Health and Welfare in 
2016, the use of e-cigarettes in Australia significantly increased between 2013 and 2016, with 
approximately one third of smokers (31%) having ever tried e-cigarettes and 4.4% currently 
using them (7). However, the role of e-cigarettes in quitting smoking is strongly debated (8). 
In the UK, there is a growing consensus among medical and public health organisations and 
societies that encouraging smokers to switch to e-cigarettes will produce population health 
gains (9). Conversely, similar organisations in other countries and some global agencies 
including the World Federation of Public Health Associations (10) and the World Medical 
Association (11) endorsed the report commissioned by World Health Organization (WHO), 
that described the current scientific evidence regarding e-cigarettes as “scant and of low 
certainty, making it difficult to draw credible inferences.” The WHO also promotes banning 
all forms of advertising and promotion of e-cigarettes, prohibiting unproven health claims 
and extending smoke-free policies to include vaping (12). 
Due to being a relatively new product, the risks of long-term use of e-cigarettes are uncertain. 
Public Health England (PHE) issued an updated report in early 2018 that reaffirmed its 
previous estimate that e-cigarettes are about 95% safer than conventional cigarettes (13). 
While there is an ongoing debate about the accuracy of this estimate, a consensus report from 
the National Academies of Sciences, Engineering, and Medicine, concluded that “there is 
conclusive evidence that completely substituting e-cigarettes for combustible tobacco 
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cigarettes reduces users’ exposure to numerous toxicants and carcinogens present in 
combustible tobacco cigarettes” and “there is substantial evidence that completely switching 
from regular use of combustible tobacco cigarettes to e-cigarettes results in reduced short-
term adverse health outcomes in several organ systems” (14). Despite these reports, there is a 
growing body of literature that suggests that the general public hold misperceptions about the 
relative harms of e-cigarettes, with many considering them to be as harmful as tobacco 
cigarettes (13, 15).  
Among smokers, the likelihood of switching from smoking to vaping appears to be associated 
with harm perceptions. A longitudinal study showed that those who perceived e-cigarettes as 
less harmful were more likely to subsequently try them (16). Although many smokers 
perceive e-cigarettes to be less risky than conventional cigarettes (17, 18) a considerable 
proportion of smokers report that they do not know whether e-cigarettes are safer than 
tobacco cigarettes, or believe they are just as harmful (19). Many smokers report being 
interested in receiving information about the safety of e-cigarettes (20). Together, these 
findings suggest a need for clear and evidence-based information on the relative harm of e-
cigarettes and combustible tobacco products. Healthcare professionals are uniquely 
positioned to provide such information to smokers and the general public. However, little 
attention has been given to how healthcare professionals perceive e-cigarettes (21). A survey 
conducted among healthcare professionals in Greece reported that while about 33% of 
respondents recommend e-cigarettes to smokers, 40% of respondents were reluctant to 
recommend these products to smokers, including for those who are unable or unwilling to 
quit by any other means (22). Similarly, in a recent cross-sectional survey conducted among 
community pharmacists in London, it was reported that 42% of respondents expressed safety 
concerns regarding excipients of e-cigarettes and 88% of them indicated the need for training 
and workshops about e-cigarettes (23).  
The regulatory framework regarding e-cigarettes varies considerably between countries. The 
laws and policies in most countries were developed based on existing tobacco or nicotine 
product regulations or through amending the tobacco control laws (24). In 2014, the 
European Parliament passed the EU Tobacco Product Directive (TPD) that suggested a series 
of policy domains for regulating e-cigarettes in terms of sale, product safety, packaging, 
advertising, taxation and restricting vaping in public spaces (25). By the end of 2016, the EU-
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TPD provisions were transposed into national policies and implemented by the UK and 14 
EU member countries (out of 24 countries) (26, 27). In the United States, the Food and Drug 
Administration (FDA) recently took responsibility of regulation of e-cigarettes as “tobacco 
products” with respect to manufacturing standards, sale, advertising and product packaging 
(28). Similarly, in New Zealand, the government recently proposed a new regulatory option, 
via amending the Smoke-free Environments Act 1990, to allow the sale and supply of e-
cigarettes and e-liquid containing nicotine as consumer products, while maintaining 
medicines regulation for e-cigarette products that claim therapeutic benefits. The amendment 
bill will also heavily restrict access to e-cigarettes by people under the age of 18 years and 
prohibit vaping in smoke-free areas (29). 
In Australia, current regulations governing e-cigarettes and personal vaporizers are complex 
and encompass tobacco control, poisons regulation, therapeutic goods, and consumer 
protection legislation (30). Nicotine is classified by Australia’s Therapeutic Goods 
Administration (TGA) as a dangerous poison (Schedule 7) except when used in approved 
smoking cessation products or for other human therapeutic use, but there are no e-cigarettes 
listed on the Australian Register of Therapeutic Goods (31). Therefore, while approved NRT 
products can be purchased from a range of commercial outlets including supermarkets and 
petrol stations, e-cigarettes containing nicotine are illegal to sell (30). However, according to 
the TGA, Australians can access nicotine for use in e-cigarettes for a therapeutic purpose 
(e.g. quitting smoking) via one of the legal pathways for accessing unapproved therapeutic 
goods, if the person holds a valid medical prescription from a medical practitioner registered 
in Australia. This includes personal importation, the Special Access Scheme, Authorised 
Prescriber Scheme and extemporaneous compounding (32, 33). The extent to which 
pharmacy staff are aware of these regulations in Australia is currently unknown. The aim of 
the present survey was to assess the opinions of pharmacy staff regarding the use and safety 
of e-cigarettes as a smoking cessation aid, as well as knowledge of current regulations and 
attitudes toward how they should be regulated.  
2. Methods  
A survey of pharmacy staff was conducted in 2015. Both pharmacists and pharmacy 
assistants were invited to participate. Pharmacists were defined as holding a minimum 
qualification of a bachelor’s degree in pharmacy and a valid licence to practice pharmacy. 
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Pharmacy assistants were defined as having completed a recognized training or certificate 
courses relevant to their role which includes supplying pharmacy only medicines under a 
pharmacist’s supervision, supplying some over-the-counter medicines and other 
administration duties (34). The self-administered questionnaire consisted of closed- and 
open-ended questions that explored: perceptions of the safety of e-cigarettes as a smoking 
cessation aid; as well as their views on how e-cigarettes are, and should be, regulated in 
Australia. Ethical approval was obtained from the University of Queensland, School of 
Pharmacy Ethics Committee. Participants were given an information sheet explaining the aim 
of the survey, confirming the anonymity of the data and provided the contact details of the 
investigators.  Informed consent from all participants was obtained before commencing data 
collection. 
A member of the research team (TD) visited a convenience sample of pharmacies within a 30 
km radius of the central business district of Brisbane, Queensland. We recruited different 
types of pharmacy premises (independent and banner group) and located in different settings 
(e.g. shopping centre, medical centre or strip mall). All pharmacy staff were approached in 
person, and were given the option to complete and return the questionnaire in the presence of 
the data collector or to complete and leave for collection the following day. The questionnaire 
was created by modifying items in a previously used data collection tool (23), and items were 
reviewed by the research team which included an experienced pharmacy practice researcher 
and a public health expert. The final data collection tool were then pilot-tested with selected 
pharmacists for understanding. The final questionnaire consisted of 20 questions that 
included multiple response (Likert scale), closed (Yes/No) and open-ended questions 
measuring  i) perceptions of the safety of NRTs and e-cigarettes and the relative harmfulness 
of e-cigarettes, NRTs and other tobacco products compared to regular tobacco cigarettes; ii) 
knowledge of current Queensland regulations concerning nicotine and non-nicotine e-
cigarette products; iii) views on how they should be regulated and iv) information needs 
regarding e-cigarettes. Finally, respondents were asked for demographic characteristics 
including age, gender, role in the pharmacy, ever use of tobacco products and e-cigarettes.  
2.1.Data analysis 
The data were entered into and analysed using Statistical Package for the Social Sciences 
(SPSS) software version 25.0 for Windows (SPSS Inc., Chicago, IL). Categorical data were 
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described using frequencies and percentages. Pearson’s chi-square test was employed for 
computing differences between pharmacists and pharmacy technicians. A p-value of less than 
0.05 was considered statistically significant. A content analysis of responses to open-ended 
questions was also performed.  
3. Results  
3.1.Demographic characteristics  
Staff from 55 of the 58 pharmacies approached participated in the survey. The pharmacies 
that participated in the survey represent 20% of all community pharmacies located within a 
30 km radius of Brisbane city centre. These pharmacies were distributed across 31 out of a 
total of 83 postal codes that fall in that area. A total of 64 (45.7%) pharmacists (including 6 
pharmacy interns) and 76 (53.3%) pharmacy assistants completed the survey (Table 1). Most 
participants had never smoked tobacco (85%) or tried e-cigarettes (88%).  
All of the pharmacies stocked and recommended a wide range of NRT products. The most 
frequently (“most of the time” or “always”) recommended types of NRTs were nicotine 
patches (61%), nicotine gum (47%) and nicotine lozenges (28%). None of the participating 
pharmacies stocked or sold e-cigarettes. 
 
Table 1.  Participant characteristics according to their pharmacy role  
Variable Total 
n=140 
Pharmacists 
n=64 
Pharmacy assistants 
n=76 
 n (%) n (%) n (%) 
Gender       
   Male 37  (26.3) 27  (42.2) 10  (13.1) 
   Female 103  (73.7) 37  (57.8) 66 (86.8) 
Age        
   16-25 72  (51.4) 26  (40.6) 46 (60.5) 
   26-35 39  (27.9) 25  (39.1) 14 (18.4) 
   35+ 29  (20.7) 13  (20.3) 16  (21) 
Smoking status (n=139)       
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   Never smoked 119  (85.6) 59  (92.2) 60  (88.9) 
   Ex-smoker 14 (9.4) 5  (7.8) 9 (11.8) 
   Current smoker  7 (5.0) 0 (0) 7  (9.2) 
Ever tried e-cigarettes       
   No 123  (87.8) 57 (89.1) 65  (85.5) 
   Yes, with nicotine 5  (3.6) 3  (4.7) 2  (2.6) 
   Yes, without nicotine 12  (8.6) 4  (6.2) 8  (10.5) 
 
The majority of participants in this survey were female (74%). Most of the males that took 
part were pharmacists, leading to a significant difference (p<0.05) in gender between 
pharmacists and pharmacy assistants. There were no other differences in baseline 
characteristics. Similarly, no significant difference was found in responses to all safety and 
regulation questions between qualifications (pharmacist vs pharmacy assistant), age, smoking 
status and ever use of e-cigarettes. Therefore all data is presented as a mean across all of the 
respondents without further subdivision. 
Compared to regular tobacco cigarettes, most participants (94%) rated NRTs as less harmful 
than regular tobacco cigarettes, though 6% believed that NRTs are equally as harmful (Figure 
1). A similar proportion regarded e-cigarettes without nicotine to be less harmful than 
tobacco cigarettes, however fewer (72%) believed that nicotine-containing e-cigarettes are 
less harmful, while 24% believed they are equally as harmful, and 4% thought they are more 
harmful than tobacco cigarettes. Responses regarding relative safety of nicotine-containing e-
cigarettes were similar to opinions on the relative safety of nicotine-free herbal cigarettes 
(Figure 1). More people disagreed (39%) than agreed (14%) with the statement that e-
cigarettes are safer than NRTs but most answered ‘neither agree nor disagree’ which may 
indicate that they consider them to be similar in terms of safety or that they didn’t have an 
opinion or knowledge (Table 2). 
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Figure 1. Perceived safety of nicotine replacement therapy (NRT) products, e-cigarettes and 
other tobacco products compared to regular tobacco cigarettes. Responses were much less / a 
little less harmful (black bars), equally harmful (grey bars) and much more / a little more 
harmful (white bars) than tobacco cigarettes. 
 
The majority of respondents (88%) agreed/strongly agreed that NRTs are safe for short term 
use. However, this dropped to 35% agreeing/strongly agreeing with NRTs being safe for long 
term use (Table 2). Respondents were much less confident about the safety of e-cigarettes, as 
36% agreed/strongly agreed that short term use of e-cigarettes would be safe, and only 15% 
indicated that long term use would be safe. Pharmacy staff were mostly negative (57-61%) 
regarding the safety of both NRT and e-cigarettes for lifetime use (Table 2). 
 
Table 2. Respondent opinions about the safety of NRTs and e-cigarettes containing nicotine. 
Variables  Disagree/strongl
y disagree 
Neither 
agree nor 
disagree 
Agree/strongl
y agree 
 n (%) n (%) n (%) 
0% 20% 40% 60% 80% 100%
Nicotine replacement therapies
E-cigarettes with nicotine
E-cigarettes without nicotine
Herbal cigarettes without nicotine
Non-smoked tobacco products such as snuff
Responses (%) 
Less harmful Equally harmful More harmful
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Safe to use for short term (<6 months)       
 NRTs (n=139) 3  (2.2) 14  (10.1) 122 (87.8) 
E-cigarettes (n=138) 30  (21.7) 59  (42.7) 49  (35.6) 
Safe to use for long term (few years)       
 NRTs (n=140) 42  (30.0) 49  (35.0) 49 (35.0) 
E-cigarettes (n=138) 65  (47.1) 53  (38.4) 20 (14.5) 
Safe to use for lifetime       
 NRTs (n=140)  85  (60.7) 36 (25.7) 19  (13.6) 
E-cigarettes (n=138) 78  (56.5) 49 (35.5) 11 (8.0) 
E-cigarettes are safer than NRTs 
(n=138)  
54  (39.1) 65  (47.1) 19  (13.8) 
 
Half of participants in this study answered “don’t know” on how e-cigarettes with nicotine 
(43.6%) and without nicotine (51.4%) or nicotine e-liquid (55%) are regulated (Table 3). The 
remainder were split between believing that it is illegal versus legal to sell in Queensland. 
Very few considered that any of these products could be obtained through a pharmacy. 
However, 46% of pharmacy staff held the opinion that e-cigarettes with nicotine and nicotine 
e-liquid should be available through pharmacies, split evenly between whether this should be 
with or without a prescription. Conversely, many were of the opinion that nicotine-containing 
e-cigarettes (27%) and nicotine liquid for use in refillable vaporisers (22%) should be 
regulated in the same way as regular tobacco cigarettes. Without nicotine, opinions were 
fairly evenly split between regulating in the same way as tobacco cigarettes (29%), sale 
through a pharmacy without a prescription (28%), and no regulation being necessary (20%).  
 
Table 3. Pharmacy staff knowledge on current regulations regarding e-cigarettes, and 
opinions on how e-cigarettes should be regulated. 
 
Statements   Nicotine 
solution* 
E-cigarettes 
with nicotine 
E-cigarettes 
without 
nicotine 
 n (%) n (%) n (%) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
11 
 
 
 
How are sales of electronic cigarettes currently regulated in Queensland? 
No regulation - can be sold by anyone to 
anyone 
21 (15.0) 17 (12.1) 35 (25.0) 
Same as tobacco cigarettes 9 (6.4) 18 (12.9) 13 (9.3) 
As pharmacy or pharmacist only products** 5 (3.6) 1 (0.7) 5 (3.6) 
Require a prescription 2 (1.4) 1 (0.7) 0 (0) 
Illegal to sell 26 (18.6) 42 (30.0) 15 (10.7) 
Don’t know 77 (55.0) 61 (43.6) 72 (51.4) 
How do you think sales of electronic cigarettes should be regulated in Queensland? 
No regulation - can be sold by anyone to 
anyone 
6  (4.3) 5  (3.6) 28  (20) 
Same as tobacco cigarettes 31  (22.1) 38  (27.1) 41  (29.3) 
As pharmacy or pharmacist only products** 34  (24.3) 31  (22.1) 39  (27.9) 
Require a prescription 30  (21.4) 33  (23.6) 10  (7.1) 
Illegal to sell 11  (7.9) 15  (10.7) 3  (2.1) 
Don’t know 28  (20) 18  (12.9) 19  (13.6) 
* For use in a refillable tank style electronic vaporizer 
** Medicines belonging to the Australian SUSMP Schedules 2 or 3. S2: Pharmacy medicine, 
S3: Pharmacist only medicine 
 
According to the survey, 39% of pharmacy staff had been asked about e-cigarettes by their 
customers and 75% of pharmacy staff believed that their customers would be interested in 
using e-cigarettes as a smoking cessation aid. The majority of respondents (91%) believed 
that pharmacy staff need more information regarding e-cigarettes. Free text responses to an 
item asking about information needs in relation to e-cigarettes were provided by 75 
respondents. The most common response was to identify a lack of knowledge, formal 
education or an absence of guidelines about e-cigarettes (39%). It was also common for 
pharmacy staff to identify a need to educate or counsel customers and to provide 
recommendations for or against use (33%). Some free-text responses noted increasing 
enquiries about e-cigarettes from customers (8%), and others thought that e-cigarettes could 
potentially help smokers quit (8%). 
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4. Discussion  
With the growing popularity and use of e-cigarettes as a way to quit smoking, it is essential 
that pharmacists have adequate and updated information in order to guide their customers in 
making evidence-based decisions. This is the first survey in Australia to examine the views of 
pharmacy staff toward the use of e-cigarettes as a smoking cessation aid, their perception of 
safety relative to cigarettes and NRTs, and knowledge and attitudes toward their regulation.  
In many countries, sale of e-cigarettes in pharmacies is common. In countries where tobacco 
products are sold in pharmacies, such as the USA, it is unsurprising that e-cigarettes are also 
sold because they are treated as if they are tobacco products (35). None of the pharmacies in 
this survey reported stocking e-cigarettes. The Pharmacy Board of Australia states that the 
sale of tobacco products is regarded as unprofessional conduct, but has not provided advice 
on the sale of e-cigarettes (36). Similar to Australia, tobacco products are not sold in UK 
pharmacies, however, in contrast to Australia, most sell e-cigarettes and professional bodies 
have positions and policies in regard to e-cigarettes. The Royal Pharmaceutical Society (RPS) 
in the UK indicate in their position statement that “where someone is unwilling to use a 
licensed NRT product, pharmacists should use their professional judgement when giving 
advice to patients and the public on the use of e-cigarettes” (37). The General Pharmaceutical 
Council (GPhC) also state that “The health, safety and well-being of patients must be the first 
concern for pharmacy owners and superintendents when deciding which products and 
services to supply in a pharmacy” (38). A study conducted in London reported that 73% of 
community pharmacies surveyed sold e-cigarettes, and more than two thirds of the 
pharmacists perceived e-cigarettes as being as safe and effective as NRTs (23). 
Disappointingly, a recent review of business compliance conducted by Trading Standards 
Services in England reported that 53% of independent pharmacies and 43% of chain 
pharmacies illegally sold e-cigarettes to minors (under 18 years old) (39).  
More than two thirds of respondents in our study believed that e-cigarettes (with or without 
nicotine) were less harmful than regular tobacco cigarettes. However, 28% viewed e-
cigarettes containing nicotine to be more harmful than or as harmful as tobacco cigarettes. 
Nicotine is a psychoactive substance responsible for addictive/craving symptoms and 
associated with mild cardiotoxicity (40), but most of the toxicants responsible for cancer and 
cardiovascular diseases are associated with combustion of tobacco and are absent from e-
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cigarette vapour or present in much lower quantities, which makes them a lower risk 
alternative to combustible cigarettes. This notion is supported by recent consensus report 
issued by the US National Academies of Science, Engineering and Medicine, which stated 
that completely replacing regular tobacco cigarettes by e-cigarettes reduces exposure to many 
toxicants and carcinogens (14). The updated PHE report also stated that e-cigarettes are about 
95% safer than conventional cigarettes and concluded that the cancer risk of e-cigarettes were 
lower than the risk of smoking combustible cigarettes (13). Both reports acknowledge the 
need for continued research on the short and long term safety of these products. 
Currently, regulation of e-cigarettes in Australia is confusing, and interpretations and 
application of current laws have varied across different jurisdictions. Tobacco intended for 
smoking is the only non-therapeutic nicotine product for human use that is exempt from the 
classification as a dangerous poison in Australia (30). The TGA have clarified that e-
cigarettes containing nicotine can be legally accessed for therapeutic purposes (e.g. quitting 
smoking) using a number of pathways for accessing unapproved therapeutic goods, including 
personal importation, the Special Access Scheme, Authorised Prescriber Scheme and 
extemporaneous compounding (32). All of these require a valid prescription from a medical 
practitioner registered in Australia, and direct-to-consumer advertising is not permitted for 
prescription medicines in Australia. However, the law has been interpreted differently by 
Queensland Health (the State Government Health Department), who have stated in a 
factsheet on e-cigarettes that “these products, once imported, are classified as a poison, not a 
therapeutic good” (41). In a magazine produced for pharmacy owners in Australia (42), the 
Pharmacy Guild of Australia stated that promoting, stocking, and/or supplying of e-cigarettes 
in pharmacies as a smoking cessation aid is against its Quality Care Pharmacy Program 
(QCPP) requirements (43), which indicates that cigarettes, tobacco or smoking-related 
products or implements should not be sold or promoted. However, there are no clear 
guidelines or policy statements provided by any of the professional organisations for 
pharmacists on how Australian pharmacy staff should handle customer enquiries about e-
cigarettes or on dispensing prescriptions for nicotine solution for use in e-cigarettes as a 
cessation aid.  
The Australian Department of Health has acknowledged there is public confusion about the 
legal status of e-cigarettes “especially in terms of the regulations that apply to their 
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importation, marketing (including sale) and use” (44). This confusion was reflected in our 
findings with pharmacy staff. There was no common understanding of current regulation of 
e-cigarettes in Australia, and a large proportion of participants reported that they did not 
know how e-cigarettes or nicotine liquid were regulated. In addition, there was no consensus 
among pharmacy staff on how e-cigarettes (with or without nicotine) should be regulated. 
Around 45% of the pharmacy staff in the present study considered that e-cigarettes 
containing nicotine should be regulated in such a way as to allow them to be available 
through a pharmacy, with half of those advising that availability should require a 
prescription. If e-cigarettes are to be regulated as “pharmacy only” or “prescription only” 
products, pharmacy staff would need to be more aware and have better understanding of 
these products. Yet others believed that they should be regulated in the same way as regular 
tobacco cigarettes (which are not sold in pharmacies in Australia). A similar lack of 
consensus was observed in terms of regulating nicotine free e-cigarettes and nicotine e-liquid.  
In our study, 39% of pharmacy staff reported being asked about e-cigarettes by their 
customers and approximately two thirds of pharmacy staff thought that their customers would 
be interested in using e-cigarettes as a smoking cessation aid. This is comparable to the 35% 
of U.S. and Canadian quit line counsellors and 48% of physicians in North Carolina who 
reported being asked about e-cigarettes by their clients (45, 46). The majority of pharmacy 
staff (91%) in our study indicated that they need more information regarding e-cigarettes. As 
a trusted source of health information, smokers are likely to consult community pharmacists 
for evidence-based advice about e-cigarettes. Clinical practice guidelines have been 
published and provide evidence-based information regarding e-cigarettes for healthcare 
professionals involved in adolescent health (47), otolaryngologists (48), cardiologists (49) 
and nurses (50).  Recently, UK’s National Centre for Smoking Cessation and Training has 
published an online training for health professionals regarding e-cigarettes and smoking 
cessation (51). Yet, there is lack of such practice guidelines for pharmacists in Australia.  
The present survey highlights an area of research where there is lack of literature in Australia. 
This study has a number of methodological limitations that should be taken into consideration 
while interpreting the findings. Firstly, the survey used for assessing the perception of 
pharmacy staff regarding electronic cigarettes had not been previously validated. Although 
we did not perform preliminary interviews which could elicit concepts and inform our survey 
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contents, we developed the survey items based on an extensive literature review. We also 
included additional free text options, allowing us to further elicit new themes. Additionally, 
as the study focussed only on a convenience sample of pharmacy staff and employed a 
descriptive cross-sectional study design, caution should be exercised when generalizing to 
other regions and territories in Australia. Nonetheless, this survey provides valuable insight 
into the existing gap in awareness of e-cigarette product characteristics and its potential 
impact on public health. 
Conclusions 
This survey was conducted in order to gain an insight into the perceptions of pharmacy staff 
regarding e-cigarettes in terms of safety, regulations and information and training needs. The 
majority of pharmacy staff believed that e-cigarettes are safe for short term use and perceived 
e-cigarettes as less harmful compared to regular tobacco cigarettes. Our results also suggest 
that consumers expect pharmacy staff to be aware of these products as the participants in our 
study reported receiving client inquiries about e-cigarettes. Thus, evidence-based and 
customised educational intervention (such as a practice guideline) for pharmacists about e-
cigarettes would be useful. However, the inconsistency in interpretation of the law by state 
and federal regulators needs to be resolved so that pharmacy staff and the public have 
confidence in their legal responsibilities.  
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Highlights 
Staff regarded e-cigarettes without nicotine as less harmful than tobacco cigarettes.  
Pharmacy staff believed that e-cigarettes with nicotine should be regulated as a medicine.  
Some pharmacy staff reported having been asked about e-cigarettes by customers  
Majority of staff indicated the need for more information regarding e-cigarettes 
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